Over the past decade, India has seen significant improvements in its clinical trial landscape, with a 15-18% growth in phase two and three trials. This growth is attributed to 10 modifications to the Drugs and Cosmetics Act since 2013, aimed at simplifying the process. Despite these advancements, conducting trials in India can still be challenging. Experts note that India’s modernizing private hospital networks and improved infrastructure make it an attractive location for trials, with potential for further growth and collaboration in the future.
